Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands	Three Months Ended March 31, 2025
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	325	$	—	$	325
Total Drug Products	325		—		325
Concentrate Products
Product Sales – Point-in-time	18,589		16,436		2,153
Total Concentrate Products	18,589		16,436		2,153
Net Revenue	$	18,914	$	16,436	$	2,478

In thousands	Three Months Ended March 31, 2024
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	11	$	—	$	11
Total Drug Products	11		—		11
Concentrate Products
Product Sales – Point-in-time	22,665		20,934		1,731
Total Concentrate Products	22,665		20,934		1,731
Net Revenue	$	22,676	$	20,934	$	1,742

Schedule of Contract Balance

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands	March 31, 2025		December 31, 2024		January 1, 2024
Accounts Receivable, net	$	9,670	$	8,291	$	10,901
Contract Liabilities, which are included in deferred license revenue	$	—	$	475	$	521